2026 Graeme J. Sills: Neuroscience Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Neuroscience	50	5687	5232	466	424	155	10962

Discipline name

D-Index

World Ranking

Current World Ranking

National Ranking

Current National Ranking

Publications

Citations

Neuroscience

5687

5232

466

424

155

10962

Overview

Graeme J. Sills is affiliated with the University of Glasgow in the United Kingdom. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. The scientist's work covers multiple subfields including Psychiatry and Mental Health, Genetics, Pediatrics, Perinatology and Child Health, Molecular Biology, and Cellular and Molecular Neuroscience.

The research topics addressed by Sills focus extensively on epilepsy and its related pharmacological and genetic dimensions. Key areas include:

Epilepsy research and treatment
Pharmacological effects and toxicity studies
Neuroscience and neuropharmacology research
Genetics and neurodevelopmental disorders
Genomics and rare diseases
Hemoglobinopathies and related disorders
Genetics, aging, and longevity in model organisms

Among the recent publications credited to Graeme J. Sills are:

"Mechanisms of action of currently used antiseizure drugs," 2020, Neuropharmacology
"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial," 2021, The Lancet
"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial," 2021, The Lancet
"The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?", 2021, Epilepsia
"Functional analysis of epilepsy-associated variants in STXBP1/Munc18-1 using humanized Caenorhabditis elegans," 2020, Epilepsia

Sills frequently publishes in the following journals:

Epilepsia
The Lancet
Neuropharmacology
Therapeutic Advances in Neurological Disorders
Pharmacogenomics

Collaboration is also notable in Sills' work. Frequent coauthors include:

Anthony G Marson
Gianpiero L. Cavalleri
Norman Delanty
Chantal Depondt
Federico Zara

Best Publications

The mechanisms of action of gabapentin and pregabalin

Graeme J Sills

802
Citations
Predictors of pharmacoresistant epilepsy.

Nikolas Hitiris;Rajiv Mohanraj;John Norrie;Graeme J. Sills

608
Citations
Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies

Bassel Abou-Khalil;Pauls Auce;Andreja Avbersek;Melanie Bahlo

470
Citations
Mechanisms of action of currently used antiseizure drugs.

Graeme J. Sills;Michael A. Rogawski

440
Citations
The mechanisms of action of commonly used antiepileptic drugs

Patrick Kwan;Graeme J Sills;Martin J Brodie

439
Citations
Combining antiepileptic drugs—Rational polytherapy?

Martin J. Brodie;Graeme J. Sills

296
Citations
Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy

Tanja Brenner;Graeme J. Sills;Graeme J. Sills;Yvonne Hart;Stephen Howell

274
Citations
Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment

Graeme J. Sills;Rajiv Mohanraj;Elaine Butler;Sheila McCrindle

272
Citations
Bone density and antiepileptic drugs: a case-controlled study.

L.J Stephen;A.R McLellan;J.H Harrison;D Shapiro

229
Citations
Ultra-rare genetic variation in common epilepsies: a case-control sequencing study.

Andrew S Allen;Susannah T Bellows;Samuel F Berkovic;Joshua Bridgers

217
Citations
Sudden unexpected death in epilepsy: a search for risk factors.

Nikolas Hitiris;Suraya Suratman;Kevin Kelly;Linda J. Stephen

203
Citations
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Anthony Marson;Girvan Burnside;Richard Appleton;Dave Smith

195
Citations
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Anthony Marson;Girvan Burnside;Richard Appleton;Dave Smith

177
Citations
Antiepileptic drug therapy: Does mechanism of action matter?

Martin J. Brodie;Athanasios Covanis;Antonio Gil-Nagel;Holger Lerche

171
Citations
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.

Graeme J. Sills;Patrick Kwan;Elaine Butler;Elizabeth C.M. de Lange

139
Citations
Current limitations of antiepileptic drug therapy: a conference review

C.L.P Deckers;P Genton;G.J Sills;D Schmidt

138
Citations
Topiramate in refractory epilepsy: a prospective observational study.

Linda J. Stephen;Graeme J. Sills;Martin J. Brodie

138
Citations
Lamotrigine and topiramate may be a useful combination.

Linda J Stephen;Graeme J Sills;Martin J Brodie

136
Citations
Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy?

Lauren Walker;Graeme J. Sills

135
Citations
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy

Lauren Elizabeth Walker;Federica Frigerio;Teresa Ravizza;Emanuele Ricci

119
Citations